Renal Function Tests (RFT) and eGFR

Renal Function Tests (RFTs) — interchangeably designated Kidney Function Tests (KFTs) or the basic renal metabolic panel — constitute the cornerstone of nephrology, fluid homeostasis monitoring, and therapeutic drug dosing across clinical medicine. The panel quantifies circulating end-products of nitrogen metabolism, specifically serum creatinine and blood urea nitrogen (BUN) / serum urea, to evaluate glomerular filtration rate (GFR), renal tubular reabsorption, and nitrogenous clearance.

In healthy adult humans, approximately 180 liters of plasma are ultrafiltered through glomerular capillary wall basement membranes each day, yielding an average physiological Glomerular Filtration Rate (GFR) of 100 to 125 mL/min/1.73m². GFR represents the gold-standard aggregate index of functioning renal nephron mass.

• Creatinine: An endogenously generated amino acid breakdown product derived from the non-enzymatic conversion of skeletal muscle creatine and phosphocreatine. Under steady-state conditions, creatinine is generated at a relatively constant daily rate proportional to total skeletal muscle mass. It is freely filtered by renal glomeruli and neither reabsorbed nor metabolized by renal tubules. However, approximately 10% to 15% of urinary creatinine is actively secreted into tubular lumens by proximal tubular organic cation transporters (OCT2). Consequently, raw creatinine clearance slightly overestimates true GFR.
• The Hyperbolic Creatinine-GFR Curve: The relationship between serum creatinine concentration and true GFR is non-linear and hyperbolic. In the "creatinine-blind zone" (GFR 60 to 120 mL/min/1.73m²), a massive 50% drop in functioning nephron mass may elevate serum creatinine only from 60 µmol/L to 95 µmol/L (still technically within the normal laboratory reference range). Conversely, once GFR drops below 30 mL/min/1.73m², even tiny reductions in nephron filtration cause dramatic surges in serum creatinine.
• Blood Urea Nitrogen (BUN) / Serum Urea: The primary end-product of hepatic protein and amino acid catabolism, synthesized via the hepatic ornithine-urea cycle to detoxify toxic ammonia. Unlike creatinine, urea is freely filtered by glomeruli and undergoes passive tubular reabsorption (40% to 50% under normal hydration, increasing up to 70% in states of low tubular flow and volume depletion).

• Muscle Mass and Dietary Intake: Ingestion of cooked red meat (which contains creatine converted to creatinine during heating) can acutely elevate serum creatinine by 10% to 20% for up to 6 to 12 hours postprandially. Ensure the patient is in a steady fasting state if monitoring borderline CKD.
• Specimen Tube & Hemolysis: Serum separator tubes (gold/red top) or lithium heparin plasma tubes (green top) are standard. Severe hemolysis releases intra-erythrocytic chromogens and enzymes that interfere with colorimetric alkaline picrate (Jaffe) reactions.
• Vigorous Physical Exertion: Intense weightlifting, crossfit training, or marathon running can transiently elevate serum creatinine through acute skeletal muscle breakdown (rhabdomyolysis) independently of renal filtration capacity.
• Hydration State: Dehydration reduces renal blood flow and activates the renin-angiotensin-aldosterone axis, maximizing proximal tubular water and urea reabsorption, selectively driving up BUN without a corresponding rise in creatinine.

Chronic Kidney Disease is confirmed when kidney damage or GFR < 60 mL/min/1.73m² persists for > 3 months:

Renal Function Tests are indicated in:

1. Diagnosis and Staging of Acute Kidney Injury (AKI): Oliguria, anuria, rising azotemia in sepsis, shock, cardiac surgery, or after nephrotoxic drug administration.
2. Chronic Kidney Disease (CKD) Screening & Surveillance: Annual screening in high-risk populations including type 1 and type 2 diabetes mellitus, systemic hypertension, systemic lupus erythematosus (SLE), and cardiovascular disease.
3. Pre-procedure and Nephrotoxic Drug Safety: Prior to administering iodinated intravenous radiocontrast media, gadolinium-based MRI agents, aminoglycosides, vancomycin, amphotericin B, cisplatin, NSAIDs, or ACE inhibitors/ARBs.
4. Therapeutic Drug Monitoring and Dose Adjustment: Renally cleared pharmaceuticals (direct oral anticoagulants, low-molecular-weight heparins, digoxin, lithium, gabapentin, metformin).
5. Systemic Fluid and Electrolyte Disturbances: Unexplained edema, refractory hypertension, metabolic acidosis, hyperkalemia, or hyperuricemic gout flares.

┌─────────────────────────────────────────────────────────────┐
│          5-STEP SYSTEMATIC RENAL PANEL PROTOCOL             │
├─────────────────────────────────────────────────────────────┤
│ Step 1: Establish Baseline and Determine Chronicity         │
│         Compare present SCr with prior historical values:   │
│         ├─ Rapid rise over hours to days: AKI               │
│         ├─ Stable elevation over >= 3 months: CKD           │
│         └─ Acute deterioration on stable baseline:          │
│            Acute-on-Chronic Kidney Injury                   │
├─────────────────────────────────────────────────────────────┤
│ Step 2: If Acute (AKI), Stage via KDIGO Criteria            │
│         ├─ Stage 1: Rise >= 26.5 umol/L (0.3 mg/dL) in 48h  │
│         │  OR 1.5 - 1.9x baseline; urine < 0.5 mL/kg/h x 6h │
│         ├─ Stage 2: Rise 2.0 - 2.9x baseline                │
│         └─ Stage 3: Rise >= 3.0x baseline OR SCr >= 353.6   │
│            umol/L (4.0 mg/dL) OR emergent RRT initiated     │
├─────────────────────────────────────────────────────────────┤
│ Step 3: Classify Etiology via BUN/Creatinine Ratio          │
│         ├─ BUN/Cr > 20:1 (> 80:1 SI): Pre-renal azotemia,  │
│         │  upper GI bleed, catabolic steroids, hypovolemia │
│         ├─ BUN/Cr 10 - 15:1 (40 - 60:1 SI): Intrinsic renal│
│         │  failure (ATN, AIN, glomerulonephritis)          │
│         └─ Variable: Post-renal obstructive uropathy        │
├─────────────────────────────────────────────────────────────┤
│ Step 4: Calculate eGFR and CrCl for Intended Purpose        │
│         ├─ Population Staging & Prognosis: CKD-EPI 2021     │
│         │  (race-free equation)                             │
│         ├─ Equivocal eGFR (45 - 59) without albuminuria:    │
│         │  Order serum Cystatin C (eGFRcys)                 │
│         └─ Drug Dosing (DOACs, Chemotherapy): Calculate     │
│            Cockcroft-Gault CrCl (mL/min, unindexed)         │
├─────────────────────────────────────────────────────────────┤
│ Step 5: Screen for Life-Threatening Uremic Emergencies      │
│         Check electrolytes & ABG: Hyperkalemia (> 6.0),     │
│         severe refractory metabolic acidosis (pH < 7.15),   │
│         fluid overload / pulmonary edema, uremic            │
│         pericarditis, or uremic encephalopathy.             │
└─────────────────────────────────────────────────────────────┘

• Cimetidine & Trimethoprim: Inhibit OCT2-mediated proximal tubular secretion of creatinine without altering true GFR. They produce a benign, reversible 15% to 30% rise in serum creatinine that does not reflect true renal injury.
• Ketoacidosis and Cephalosporins (Jaffe Reaction Interference): Acetoacetate in diabetic ketoacidosis (DKA) and certain first/second-generation cephalosporins (cefoxitin, cefazolin) react directly with alkaline picrate reagents in automated colorimetric Jaffe assays, causing artifactual overestimation of serum creatinine by up to 50% to 100%. Modern enzymatic creatinine assays eliminate this interference.
• Fenofibrate: Increases metabolic creatinine production and reversibly elevates serum creatinine by 15% to 20%.
• SGLT2 Inhibitors: Induce an expected, hemodynamically mediated initial dip in eGFR of 3 to 5 mL/min/1.73m² within 2 to 4 weeks of initiation due to restored tubuloglomerular feedback and afferent arteriolar constriction. This initial dip is reversible and confers long-term nephroprotection; the drug should NOT be stopped.

1. The "Sarcopenic Elderly Patient" Trap: In frail elderly patients, patients with limb amputations, quadriplegia, or end-stage liver disease, serum creatinine may be 35 to 50 µmol/L (0.4–0.6 mg/dL). When such a patient develops acute tubular necrosis, a rise from 40 to 80 µmol/L represents a devastating 50% loss of GFR despite the absolute creatinine number appearing completely "normal" on standard laboratory flags.
2. Applying CKD Equations to Acute Kidney Injury: The mathematical models underlying CKD-EPI, MDRD, and Cockcroft-Gault assume steady-state creatinine balance where generation equals excretion. During acute kidney injury, serum creatinine lags hours to days behind instantaneous GFR collapse, rendering eGFR numbers clinically invalid.
3. Misapplying Indexed eGFR to Drug Dosing: CKD-EPI eGFR is normalized to standard body surface area (mL/min/1.73m²). In patients whose BSA deviates markedly from 1.73 m² (morbidly obese or very small individuals), failing to de-index eGFR or calculate Cockcroft-Gault CrCl leads to dangerous medication overdosing or underdosing.

• The BUN/Cr Ratio Magic Number: If BUN/Cr > 20:1 → Think pre-renal azotemia, dehydration, or upper GI bleeding (digested blood protein is absorbed as urea). If BUN/Cr < 10–15:1 → Think intrinsic renal damage (ATN).
• The "FeNa" vs "FeUrea" Diuretic Rule: In a patient taking loop diuretics (furosemide), FeNa is falsely elevated (> 1%) because the diuretic forces urinary sodium wasting. In this clinical scenario, calculate Fractional Excretion of Urea (FeUrea): a value < 35% confirms pre-renal azotemia despite high urine sodium.
• Why Jaffe Failed: Thomas Jaffe in 1886 discovered that picric acid in alkaline solution reacts with creatinine to produce a red-orange color. Ketone bodies, cephalosporins, and bilirubin cause non-specific color development, giving false readings. Modern laboratories use enzymatic creatinine amidohydrolase assays.
• The ACEi/ARB 30% Rule: Initiation of an ACE inhibitor or ARB causes efferent arteriolar vasodilation, dropping intraglomerular capillary pressure. An acute creatinine rise of up to 30% above baseline within 2 to 4 weeks is physiologically expected and acceptable; do NOT discontinue the drug unless the rise exceeds 30% or refractory hyperkalemia ensues.

• Serum Electrolytes: Mandatory companion panel assessing sodium, potassium, chloride, and bicarbonate (Serum Electrolytes).
• Routine Urinalysis and Microscopy: Essential to examine specific gravity, proteinuria, hematuria, and diagnostic casts (Routine Urinalysis).
• Urine Albumin-to-Creatinine Ratio (uACR): Quantifies early glomerular basement membrane injury and classifies CKD risk (Urine Protein).
• Arterial Blood Gas (ABG): Diagnoses metabolic acidosis and anion gap calculation in renal failure (Arterial Blood Gas).
• Renal Tract Ultrasound: First-line imaging to exclude post-renal hydronephrosis and assess renal cortical thickness and bipolar length (< 9 cm indicates chronic irreversible atrophy).